Pfizer forecast flat US drug prices in 2019 and downplayed large M&A as a way to assuage near-term growth concerns, while investors brace for a challenging period cycling through the loss of Lyrica.
Pfizer Inc. CEO Albert Bourla led his first earnings call as the company's chief executive Jan. 29 and stuck to a similar message the company has laid out to investors for close to a year: that Pfizer will be well positioned for growth after cycling through the loss of Lyrica to generics beginning June 30, 2019.
Growth will come largely from innovation and the company's internal R&D engine, Bourla said, calling large-scale M&A a potential distraction...
The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.
The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.
Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.
The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.
The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.
Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.
50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis
